The
new INCOGNITO™ kits
Evade cellular immune response to your RNA with the new INCOGNITO™ kits from Cellscript.
The
new INCOGNITO™ kits * are designed for in vitro synthesis of RNA containing
modified nucleosides such as pseudouridine and 5-methylcytidine. They assist in
reducing immune response and enhancing protein translation. A range of these kits are available to end
users depending on their specific research desires and downstream applications.
Cellscript’s INCOGNITO™ contain everything needed to
make N1meΨ- or Ψ-containing Cap1 mRNA, including in vitro transcription
reagents plus ScriptCap™ Capping Enzyme, ScriptCap™ 2’-O-Methyltransferase, and
A-Plus™ Poly(A) Polymerase. - INCOGNITO™ T7-FlashScribe™
INCOGNITO™ T7 mScript™ mRNA Production Systems contain
everything needed to make N1meΨ- or Ψ-containing Cap1 mRNA, including in vitro
transcription reagents plus ScriptCap™ Capping Enzyme, ScriptCap™
2’-O-Methyltransferase, and A-Plus™ Poly(A) Polymerase. - INCOGNITO™
T7-FlashScribe
The INCOGNITO™ SP6 Ψ-RNA Transcription Kit -optimized
for high-yield synthesis of pseudouridine-containing RNA (Ψ-RNA) from an in
vitro transcription (IVT) reaction.
The INCOGNITO™ T7 5mC- & Ψ-RNA Transcription Kit -
optimized for high-yield synthesis of 5-methyl-cytidine-
pseudouridine-containing RNA (5mCΨ-RNA) from an in vitro transcription
(IVT) reaction.
Advantages
- Optimized for high-yield synthesis of pseudouridine-containing IVT RNA (Ψ-RNA)
- Produce up to 100 µg of Ψ-RNA from 1 µg of template ( depending on kit used).
- Easily scale up reactions to produce milligram amounts of Ψ-RNA.
- Lower immunogenicity in mammalian cells through incorporation of Ψ in synthesized mRNA.
- Modified Ψ-mRNAs translate into higher protein levels
- The standard reactions can be scaled up to produce milligram amounts of RNA canonical nucleotides ATP and GTP and modified pseudouridine-5'-triphosphate (ΨTP) and 5-methyl-cytidine-5'-triphosphate (5mCTP).
*Transcription Kits are for in vitro transcription of N1meΨ- or Ψ-containing RNA. - All kits above come with a label license to use them for internal research use under the University of Pennsylvania’s modified mRNA technologies patents.